BAY-707 (BAY707) is a highly potent, selective and substrate-competitive inhibitor of MTH1 (NUDT1) with IC50 of 2.3 nM.
BAY-707 demonstrates high selectivity in an in-house kinase panel, and shows an overall favorable physicochemical profile and in vitro pharmacokinetic properties with high metabolic stability.
BAY-707 demonstrates a superior cellular target engagement with an EC50 of 7.6 nM compared with TH588, increases the cellular thermal stabilization of MTH1 with no effect on the expression of MTH2, OGG1, and MUTYH.
BAY-707 shows a clear lack of in vitro or in vivo anticancer efficacy either in mono- or in combination therapies in vivo.
